Related Experiment Video

Updated: Aug 7, 2026

Studying Left Ventricular Reverse Remodeling by Aortic Debanding in Rodents
07:26

Studying Left Ventricular Reverse Remodeling by Aortic Debanding in Rodents

Published on: July 14, 2021

Reversal of structural changes in hypertensive arteries--a major prospect for the future

C Rosendorff1

  • 1Department of Physiology, University of the Witwatersrand.

South African Medical Journal = Suid-Afrikaanse Tydskrif Vir Geneeskunde
|September 21, 1991
PubMed

Insights

Angiotensin-converting enzyme (ACE) inhibitors can reverse vascular hypertrophy associated with hypertension. Different ACE inhibitors show varying effects on blood pressure and medial hypertrophy regression in rats.

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology

Background:

  • Arteriosclerosis, characterized by vascular smooth muscle hypertrophy and hyperplasia, is a key feature of hypertension and its complications.
  • Angiotensin II acts as a significant growth factor for vascular smooth muscle cells, contributing to arteriosclerotic changes.

Purpose of the Study:

  • To investigate the effects of chronic Angiotensin-converting enzyme (ACE) inhibitor administration on vascular hypertrophy.
  • To assess the potential of ACE inhibitors in improving vascular compliance in hypertensive patients.

Main Methods:

  • Utilized experimental animal models of hypertension, specifically spontaneously hypertensive rats.
  • Administered ACE inhibitors chronically to assess morphological and functional changes in vascular smooth muscle.

Main Results:

  • Chronic ACE inhibitor administration reversed many vascular hypertrophy changes in experimental models.
  • ACE inhibitors improved vascular compliance in hypertensive patients.
  • Observed variations among different ACE inhibitors regarding blood pressure reduction and medial hypertrophy regression in spontaneously hypertensive rats.

Conclusions:

  • ACE inhibitors demonstrate a therapeutic potential in mitigating hypertension-induced vascular hypertrophy and improving vascular function.
  • Further research is warranted to understand inter-drug differences in ACE inhibitor efficacy for vascular remodeling.

More Related Videos

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis08:21

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

Published on: October 26, 2020

A Model of Reverse Vascular Remodeling in Pulmonary Hypertension Due to Left Heart Disease by Aortic Debanding in Rats07:41

A Model of Reverse Vascular Remodeling in Pulmonary Hypertension Due to Left Heart Disease by Aortic Debanding in Rats

Published on: March 1, 2022

Related Concept Videos

Hypertension and Regulation of Blood Pressure01:18

Hypertension and Regulation of Blood Pressure

Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...